SEC Form 4 · accession 0001209191-16-100283
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Annett
Officer — President and CEO · Director
Period of report
Feb 16, 2016
Accepted (ET)
Feb 18, 2016 · 8:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $3.06 | Feb 16, 2016 | A | 250,000 | A | — | Feb 15, 2026 | Common Stock | 250,000 | 250,000 | D |
| Option to Purchase Common StockF2 | $2.20 | holding | — | — | — | — | Jun 15, 2025 | Common Stock | 605,000 | 605,000 | D |
| Option to Purchase Common StockF3 | $2.20 | holding | — | — | — | — | Jan 8, 2025 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1One quarter of the options shall vest on February 15, 2017, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- F2One quarter of the options shall vest on June 15, 2016, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- F3Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant on January 9, 2015.